Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
Abstract Background Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and efficacy in a real-world setting. This study aims to assess how clinical o...
Saved in:
Main Authors: | Shaun J. Kilty, Andrea Lasso |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-04-01
|
Series: | Journal of Otolaryngology - Head and Neck Surgery |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40463-022-00570-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission
by: Mona Al-Ahmad, MD, FRCPC, et al.
Published: (2025-02-01) -
Olfactory impairment in Italian patients with chronic rhinosinusitis with nasal polyps: a patient-centered survey
by: Francesca Anastasi, et al.
Published: (2025-01-01) -
The influence of the sinonasal microbiome on the development and management of rhinosinusitis
by: Miriam Lang, et al.
Published: (2025-01-01) -
The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
by: Nicholas J. Campion, et al.
Published: (2023-09-01) -
Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
by: Yutong Sima, MD, et al.
Published: (2025-01-01)